Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Zhengye Biotechnology Holding Limited (ZYBT)

11.35
-1.78
(-13.56%)
As of 1:04:56 PM EDT. Market Open.
Loading Chart for ZYBT
  • Previous Close 13.13
  • Open 12.73
  • Bid 12.57 x 100
  • Ask 13.33 x 100
  • Day's Range 9.88 - 13.50
  • 52 Week Range 3.50 - 14.30
  • Volume 101,835
  • Avg. Volume 343,628
  • Market Cap (intraday) 537.892M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 189.17
  • EPS (TTM) 0.06
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

www.jlzybio.com

278

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ZYBT

View More

Performance Overview: ZYBT

Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ZYBT
201.06%
S&P 500 (^GSPC)
4.24%

1-Year Return

ZYBT
201.06%
S&P 500 (^GSPC)
8.57%

3-Year Return

ZYBT
201.06%
S&P 500 (^GSPC)
36.60%

5-Year Return

ZYBT
201.06%
S&P 500 (^GSPC)
95.49%

Compare To: ZYBT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZYBT

View More

Valuation Measures

Annual
As of 5/6/2025
  • Market Cap

    622.25M

  • Enterprise Value

    633.09M

  • Trailing P/E

    222.01

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    23.74

  • Price/Book (mrq)

    16.07

  • Enterprise Value/Revenue

    24.27

  • Enterprise Value/EBITDA

    80.26

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.69%

  • Return on Assets (ttm)

    3.82%

  • Return on Equity (ttm)

    7.15%

  • Revenue (ttm)

    189.75M

  • Net Income Avi to Common (ttm)

    20.29M

  • Diluted EPS (ttm)

    0.06

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.52M

  • Total Debt/Equity (mrq)

    24.98%

  • Levered Free Cash Flow (ttm)

    -21.93M

Research Analysis: ZYBT

View More

Company Insights: ZYBT

Research Reports: ZYBT

View More

People Also Watch